{
Sanofi

Companies

}
001122334455554433221100
001122334455554433221100
Symbol SNY
Name Sanofi
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Pharmaceuticals
Market NASDAQ Global Select
Country France
State
City Paris
Zipcode 75008
Website http://www.sanofi.com
Track all markets on TradingView

stocks decline as dow extends losing streak ahead of fed decision

Stocks slipped as the Dow fell for the ninth consecutive day, its longest slump since 1978, ahead of the Federal Reserve's rate decision. Teva and Sanofi shares soared after positive drug trial results, while Amentum and EVgo faced declines due to concerns over future growth and investor sell-offs, respectively. Pfizer's shares rose after affirming its 2024 projections and providing a 2025 outlook in line with expectations.
Investopedia
United States Dollar Pfizer Inc. Jacobs Solutions Inc. EVgo, Inc. Amentum Holdings, Inc. Sanofi USA Jerome Powell Aaron McDade Taylor Tompkins Houman Ashrafian Travis Johnson Show more
Finance & Economy, Market Report
13:56 17.12.2024

duvakitug shows promise as best in class for inflammatory bowel disease

Teva and Sanofi's experimental drug, duvakitug, demonstrated significant efficacy in a Phase 2 trial for inflammatory bowel disease, with around 50% of ulcerative colitis patients and 48% of Crohn’s disease patients showing symptom resolution compared to placebo. The companies plan to advance to late-stage development, highlighting duvakitug's potential as a leading treatment in a competitive market. Following the promising results, Teva's shares surged nearly 20%, while Sanofi's rose by almost 5%.
BioPharma Dive
Merck & Co., Inc. Hoffmann-La Roche AG ABBVIE Sanofi FRA Houman Ashrafian Show more
Healthcare, Market Report
01:00 17.12.2024

global bisoprolol fumarate market poised for significant growth through 2032

The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
openPR.com
United States Dollar Merck & Co., Inc. Amgen Inc. Alkem Laboratories Limited Mylan Pharmaceuticals Inc. Aurobindo Pharma Limited Teva Pharmaceutical Industries Ltd Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Limited CIPLA LTD Sandoz Group AG Pfizer Inc. Bayer AG Hikma Pharmaceuticals PLC AstraZeneca PLC Novartis AG Torrent Pharmaceuticals Limited Sanofi IND ROU BEL HUN DNK POL IDN SGP ARE BRA ZAF FRA THA MEX CZE GBR CHL AUT SAU SWE NOR NLD USA ARG MYS SVK CAN NZL LKA JPN DEU RUS KOR CHN VNM Nidhi Bhavsar Show more
Regulatory & Legal, Market Report
13:09 16.12.2024

global bromhexine tablet market projected to reach 1131 million by 2032

The Global Bromhexine Tablet market is projected to grow from USD 875.5 million in 2023 to USD 1,131.7 million by 2032, with a CAGR of 3.7% from 2024 to 2032. This growth is driven by the rising prevalence of respiratory disorders and increasing demand for expectorants. Key players include Sanofi, Teva, and Boehringer Ingelheim, with market segmentation covering applications, types, and distribution channels across various regions.
openPR.com
GSK plc Aspen Pharmacare Holdings Ltd Boehringer Ingelheim KG Novartis AG Sanofi MYS IND PHL IDN HKG SGP TWN JPN THA AUS KOR CHN VNM Nidhi Bhavsar Show more
Healthcare, Market Report
08:02 14.12.2024

gilead appoints dietmar berger as new chief medical officer from sanofi

Gilead Sciences has appointed Dietmar Berger, M.D., Ph.D., as its new chief medical officer, recruiting him from Sanofi to replace Merdad Parsey. Berger, a cancer specialist with extensive experience at Genentech and Sanofi, will oversee Gilead's oncology pipeline, which is crucial for the company's growth strategy. He is set to start on January 2, 2024, as Gilead aims to enhance its oncology business amid significant clinical developments.
Fierce Biotech
United States Dollar Hoffmann-La Roche AG Gilead Sciences, Inc. Bayer AG Immunomedics Inc. Genentech Amgen Inc. Sanofi USA FRA John S. Reed Houman Ashrafian Daniel O'Day Merdad Parsey Dietmar Berger Show more
Healthcare, News Article
11:20 13.12.2024

Global Mobile Medicine Market Trends and Opportunities for Growth 2024 to 2031

The Mobile Medicine market is rapidly evolving, driven by innovative technologies and a competitive landscape featuring key players like Philips Healthcare, Apple, and Samsung. The market report highlights regional growth assessments, product segmentation, and forecasts from 2024 to 2031, focusing on applications in cardiovascular, diabetes, and respiratory diseases. Comprehensive analyses of market trends, driving factors, and the impact of COVID-19 provide insights into investment opportunities across North America, Europe, Asia-Pacific, and Latin America.
rock-news.at
United States Dollar Euro BOSTON SCIENTIFIC Omron Healthcare NIKE, Inc. Huawei Technologies CO. Ltd. Athenahealth Inc. Philips Healthcare XIAOMI-W Sanofi Fitbit Bayer HealthCare AG Apple Inc. Masimo Corp Samsung Biologics Co.,Ltd. Qualcomm Inc Medtronic plc AT&T Inc. Gauri Dabi Show more
Healthcare, Market Report
10:57 05.12.2024

Global Generic Pharmaceuticals Market Sees Growth in Simple Generics and Biosimilars

India's "Pharmaceuticals Mission" aims to boost generic production, with simple generics leading the market due to cost-effectiveness and ease of manufacturing. Cardiovascular diseases drive demand, while small molecules dominate product types. Retail pharmacies remain the preferred distribution channel, and key players like Cipla and Teva are expanding their offerings.
GlobeNewswire News Room
United States Dollar Euro Fresenius Kabi AG Sanofi Aspen Pharmacare Holdings Ltd Sun Pharmaceuticals, Ltd. Aurobindo Pharma Limited Glenmark Pharmaceuticals Limited Pfizer Inc. Lupin Limited Dr. Reddy's Laboratories Limited Zydus Lifesciences Limited Teva Pharmaceuticals, Inc. Viatris Inc. Novartis AG Hikma Cipla Limited IND USA Show more
Healthcare, Market Report
16:30 04.12.2024

Republican Control Promises Major Shifts in Healthcare and Pharma Policies

The incoming Trump administration and a Republican-controlled Congress are expected to significantly impact healthcare policy, particularly regarding the Affordable Care Act, Medicaid, and Medicare drug price negotiations. Analysts predict a net negative effect on healthcare companies' credit ratings due to potential increases in uninsured populations and regulatory changes, while decreased scrutiny on mergers and acquisitions may benefit the pharmaceutical sector. Additionally, rising tariffs on medical supplies could further strain the industry amid ongoing inflationary pressures.
Fierce Healthcare
United States Dollar AstraZeneca PLC Sanofi Merck & Co., Inc. Pfizer Inc. GSK plc IND USA CHN Mike Johnson Robert F. Kennedy Jr. Donald Trump Lina Khan Show more
Healthcare, Market Report
23:30 03.12.2024

AstraZeneca's Enhertu approved for reimbursement in China amid ongoing probe

AstraZeneca’s Enhertu, a leading breast cancer treatment, has been approved for reimbursement by China’s state-run medical insurance, enhancing the company’s sales prospects amid an ongoing investigation involving some senior executives. The drug is one of 91 added to the National Reimbursement Drug List, effective January 1, alongside treatments from Johnson & Johnson, Bristol Myers Squibb, Roche, Sanofi, and Merck for various conditions.
Bloomberg.com
United States Dollar Sanofi Merck & Co., Inc. Bristol-Myers Squibb Company Roche Holding AG AstraZeneca PLC Johnson & Johnson GBR Brian Johnson Show more
Healthcare, News Article
08:22 28.11.2024

frontotemporal dementia market growth trends and future projections 2024 to 2031

The Global Frontotemporal Dementia Market is projected to grow from USD 12.19 billion in 2024 to USD 18.21 billion by 2031, at a CAGR of 5.9%. Key players include Johnson & Johnson, Sanofi S.A., and Eli Lilly, with insights into market trends, competitive landscape, and future growth opportunities detailed in a comprehensive report.
openPR.com
United States Dollar Novartis AG Sanofi Mylan N.V. Merck & Co., Inc. Glaxosmithkline plc Eli Lilly and Company USA Priya Pandey Viju Shah Show more
Healthcare, Market Report
13:42 27.11.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.